Insights into gastrointestinal microbiota-generated ginsenoside metabolites and their bioactivities

Abstract

The gastrointestinal microbiota and host co-evolve into a complex ‘super-organism,’ and this relationship plays a vital role in many physiological processes, such as drug metabolism. Ginseng is an important medicinal resource and the main ingredients are ginsenosides, which are less polar, difficult to absorb, and have low bioavailability. However, studies have shown that the biological activity of ginsenosides such as compound K (CK), ginsenoside Rg3 (Rg3), ginsenoside Rh2 (Rh2), 20(S)-protopanaxatriol (20(S)-PPT), and 20(S)-protopanaxadiol (20(S)-PPD) is closely related to the gastrointestinal microbiota. In this paper, the metabolic pathway of gastrointestinal microbiota-generated ginsenosides and the main pharmacological effects of these metabolites are discussed. Furthermore, our study provides a new insight into the discovery of novel drugs. Specifically, in new drug screening process, candidates with low biological activity and bioavailability should not be excluded. Because their metabolites may exhibit good pharmacological effects due to the involvement of the gastrointestinal microbiota. In addition, in further research studies to develop probiotics, a combination of agents could exert greater efficacy than single agents. Moreover, differences in lifestyle and diet lead to differences in the gastrointestinal microbiota in the human body. Therefore, administration of the same drug dose to different individuals could elicit different therapeutic effects, owing to the involvement of the gastrointestinal microbiota. Thus, treatment accuracy could be achieved by detecting the gastrointestinal microbiota before drug treatment.

Highlights

• Gastrointestinal microbiota plays a decisive role in bioactivities of ginsenosides.

• The metabolic pathway and main pharmacological effects of ginsenoside metabolites are discussed.

• It provides new insights into novel drug discovery and further research to find probiotic, combinations to exert greater efficacy.

• Differences in lifestyle and diet, varies the gastrointestinal microbiota in the human body. However, the same dose of a drug producing different therapeutic effects may involve gastrointestinal microbiota.

Keywords:

• Gastrointestinal microbiota
• ginsenosides
• metabolic pathway
• metabolite bioactivity
• super-organism

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was supported by the Research of Major Disease Prevention and Control of Precision Medical Research of Hunan Province Education Department under Grant no. 2016JC2069, National Development of Key Novel Drugs for Special Projects of China under Grant nos. [2018ZX09736007-004, 2017ZX09304014-02, and 2018ZX09736-07].